Medindia
Medindia LOGIN REGISTER
Advertisement

Selvita Reports First Quarter 2019 Financial Results and Provides Corporate Update

Wednesday, May 22, 2019 General News
Advertisement
- Investigational New Drug (IND) application to conduct a Phase 1 study of selective CDK8 inhibitor SEL120 cleared by U.S. Food and Drug Administration (FDA)

SELVITA CRO

Consolidated Statements of Operations

 (In thousands)

Three Months EndedMarch 31,

2019

2018

External revenue

4,580

3,601

Internal revenue

145

225

Grant revenue

231

191

Total revenue

4,956

4,016

Operating expenses

4,448

3,443

EBIT

508

574

EBITDA (with IFRS16 impact -> only Q1 2019)

1,170

848

EBITDA (IFRS16 impact excluded)

944

848

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close